Wednesday, June 24, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 900 of 1,261

  1. US 8304385

    Macrocyclic tetrazolyl hepatitis C serine protease inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Nov 6, 2012 · Expires Nov 1, 2032

    granted

  2. US 8304408

    Wnt signaling inhibitors, and methods for making and using them

    The Regents of the University of California · Granted Nov 6, 2012 · Expires Nov 1, 2032

    granted

  3. US 8304422

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Nov 6, 2012 · Expires Nov 1, 2032

    granted

  4. US 8304577

    Modulators of G protein-coupled receptor 88

    LEXICON PHARMACEUTICALS, INC. · Granted Nov 6, 2012 · Expires Nov 1, 2032

    granted

  5. US 8299173

    Method involving 1-benzotriazolyl carbonate esters of polymers

    Nektar Therapeutics · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  6. US 8299050

    Method for treating uterine fibroids

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  7. US 8299087

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  8. US 8299100

    Potent and selective neuronal nitric oxide synthase inhibitors with improved membrane permeability

    Northwestern University · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  9. US 8299099

    Heteroaryl derivatives as CFTR modulators

    Vertex Pharmaceuticals Incorporated · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  10. US 8299101

    1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive mGluR2-receptor modulators

    Addex Pharma, S.A. · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  11. US 8299218

    Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

    The Regents of the University of California · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  12. US 8298576

    Sustained-release formulations of topiramate

    Supernus Pharmaceuticals, Inc. · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  13. US 8298580

    Sustained-release formulations of topiramate

    Supernus Pharmaceuticals, Inc. · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  14. US 8298589

    Nitrite formulations and their use as nitric oxide prodrugs

    The Board of Regents of the University of Texas System · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  15. US 8299033

    Iodo-hexose compounds useful to treat cancer

    The Board of Regents of the University of Texas System · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  16. US 8299040

    Methods for treating cancer targeting transglutaminase

    The Board of Regents of the University of Texas System · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  17. US 8299105

    1,2,4-oxadiazole benzoic acid compositions and their use in bioassays

    PTC THERAPEUTICS, INC. · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  18. US 8299261

    1-heterocyclylsulfonyl, 3-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors

    Takeda Pharmaceutical Company Limited · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  19. US 8298606

    Methods and compositions for stabilizing the myocardium

    The Regents of the University of California · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  20. US 8298542

    Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of Chlamydia

    The Board of Regents of the University of Texas System · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  21. US 8298541

    Live attenuated virus vaccines for La Crosse virus and other Bunyaviridae

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  22. US 8298532

    Fusion polypeptides capable of activating receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  23. US 8298523

    Compositions containing interleukin-1 and peptides

    United Technologies UT AG · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

  24. US 8298521

    Treatment for eye disorder

    The Regents of the University of California · Granted Oct 30, 2012 · Expires Oct 25, 2032

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.